Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Water Res ; 243: 120386, 2023 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-37494741

RESUMEN

Identifying sources of pollutants in watersheds is critical to accurately predicting stormwater quality. Many existing software used to model stormwater quality rely on decades-old data sets which may not represent current runoff quality in the United States. Because of environmental regulations promulgated at the federal level over previous decades, there is a need to understand long-term trends (and potential shifts) in runoff quality to better parameterize models. Pollutant event mean concentrations (EMCs) from the National Stormwater Quality Database (NSQD) were combined with those from recent sources to understand if untreated stormwater quality has changed over the past 40 years. A significant decreasing monotonic trend (i.e., continually decreasing in a nonuniform fashion) was observed for total suspended solids (TSS), total phosphorus (TP), total Kjeldahl nitrogen (TKN), total copper (Cu), total lead (Pb), and total zinc (Zn) in the resultant database, suggesting that runoff quality has become less polluted with time. Median EMCs decreased from 99.2 to 42 mg/L, 0.34 to 0.26 mg/L, 1.27 to 1.03 mg/L, 40 to 6.8 µg/L, 110 to 3.7 µg/L, and 375 to 53.3 µg/L for TSS, TP, TN, Cu, Pb, and Zn, respectively, from the 1980s to the 2010s. These significant reductions often aligned temporally with advancements in clean manufacturing, amendments of the Clean Air Act, and other source control efforts which impact pollutant bioavailability and atmospheric deposition. Results suggest environmental regulations not specifically targeting stormwater management have had a positive impact on stormwater quality and that temporal fluctuations should be considered in modeling.


Asunto(s)
Contaminantes Ambientales , Contaminantes Químicos del Agua , Estados Unidos , Contaminantes Químicos del Agua/análisis , Plomo , Zinc/análisis , Fósforo , Monitoreo del Ambiente/métodos , Lluvia , Movimientos del Agua
2.
Nat Commun ; 6: 6838, 2015 Apr 27.
Artículo en Inglés | MEDLINE | ID: mdl-25913720

RESUMEN

Histone deacetylase inhibitors (HDACi) are approved for treating certain haematological malignancies, however, recent evidence also illustrates they are modulators of the immune system. In experimental models, HDACi are particularly potent against malignancies originating from the B-lymphocyte lineage. Here we examine the ability of this class of compounds to modify both protective and autoimmune antibody responses. In vitro, HDACi affect B-cell proliferation, survival and differentiation in an HDAC-class-dependent manner. Strikingly, treatment of lupus-prone Mrl/lpr mice with the HDACi panobinostat significantly reduces autoreactive plasma-cell numbers, autoantibodies and nephritis, while other immune parameters remain largely unaffected. Immunized control mice treated with panobinostat or the clinically approved HDACi vorinostat have significantly impaired primary antibody responses, but these treatments surprisingly spare circulating memory B cells. These studies indicate that panobinostat is a potential therapy for B-cell-driven autoimmune conditions and HDACi do not induce major long-term detrimental effects on B-cell memory.


Asunto(s)
Linfocitos B/efectos de los fármacos , Inhibidores de Histona Desacetilasas/farmacología , Ácidos Hidroxámicos/farmacología , Indoles/farmacología , Animales , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Evaluación Preclínica de Medicamentos , Femenino , Centro Germinal/efectos de los fármacos , Inhibidores de Histona Desacetilasas/uso terapéutico , Ácidos Hidroxámicos/uso terapéutico , Memoria Inmunológica/efectos de los fármacos , Indoles/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Masculino , Ratones Endogámicos C57BL , Panobinostat
3.
Am J Physiol Endocrinol Metab ; 285(5): E1127-34, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14534079

RESUMEN

Normal development of both human and rat brain is associated with a switch in metabolic fuel from a combination of glucose and ketone bodies in the immature brain to a nearly total reliance on glucose in the adult. The delivery of glucose, lactate, and ketone bodies from the blood to the brain requires specific transporter proteins, glucose and monocarboxylic acid transporter proteins (GLUTs and MCTs), respectively. Developmental expression of the GLUTs in rat brain, i.e., 55-kDa GLUT1 in the blood-brain barrier (BBB), 45-kDa GLUT1 and GLUT3 in vascular-free brain, corresponds to maturational increases in cerebral glucose uptake and utilization. It has been suggested that MCT expression peaks during suckling and sharply declines thereafter, although a comparable detailed study has not been done. This study investigated the temporal and regional expression of MCT1 and MCT2 mRNA and protein in the BBB and the nonvascular brain during postnatal development in the rat. The results confirmed maximal MCT1 mRNA and protein expression in the BBB during suckling and a decline with maturation, coincident with the switch to glucose as the predominant cerebral fuel. However, nonvascular MCT1 and MCT2 levels do not reflect changes in cerebral energy metabolism, suggesting a more complex regulation. Although MCT1 assumes a predominantly glial expression in postweanling brain, the concentration remains fairly constant, as does that of MCT2 in neurons. The maintenance of nonvascular MCT levels in the adult brain implies a major role for these proteins, in concert with the GLUTs in both neurons and astrocytes, to transfer glycolytic intermediates during cerebral energy metabolism.


Asunto(s)
Química Encefálica , Encéfalo/crecimiento & desarrollo , Regulación del Desarrollo de la Expresión Génica , Transportadores de Ácidos Monocarboxílicos/genética , Proteínas de Transporte de Monosacáridos/genética , Proteínas del Tejido Nervioso , Ácido 3-Hidroxibutírico/sangre , Envejecimiento , Animales , Glucemia/análisis , Barrera Hematoencefálica , Encéfalo/metabolismo , Cerebelo/química , Metabolismo Energético , Lóbulo Frontal/química , Transportador de Glucosa de Tipo 1 , Transportador de Glucosa de Tipo 3 , Hipocampo/química , Cuerpos Cetónicos/metabolismo , Ácido Láctico/sangre , ARN Mensajero/análisis , Ratas , Ratas Wistar , Simportadores/genética , Tálamo/química , Destete
4.
Womens Health Issues ; 13(2): 74-8, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12732444

RESUMEN

The primary objective of this study was to observe the effect of hypnosis on hot flashes (HF) and overall quality of life in symptomatic patients. A secondary objective was to observe the effect of hypnosis on fatigue. Ten healthy volunteers and four breast cancer patients (total 14 patients) with symptoms of HF were treated with four, 1 h/wk sessions of hypnosis. The same physician, with the help of a nurse, conducted every session. All subjects recorded frequency, duration, and severity of HF in a HF diary. The QLQ-C30 and Brief Fatigue Inventory forms were used to assess the impact on quality of life and fatigue, respectively. The statistical evaluations were performed, including analysis of variance and nonparametric procedures. The frequency (p < 0.0001), duration (p < 0.0001), and severity (p < 0.0001) of HF were significantly reduced. The overall quality of life was also improved (p = 0.05). The subjects enjoyed better sleep and had less insomnia (p = 0.012). There was a significant improvement on current fatigue level (p = 0.017), but we did not find a statistically significant reduction in the total fatigue level. We conclude that hypnosis appears to be a feasible and promising intervention for HF, with a potential to improve quality of life and insomnia. Although improvement in current level of fatigue was observed in this pilot study, total fatigue improvement did not reach statistical significance.


Asunto(s)
Fatiga/terapia , Sofocos/terapia , Hipnosis , Menopausia/fisiología , Calidad de Vida , Trastornos del Inicio y del Mantenimiento del Sueño/terapia , Adulto , Análisis de Varianza , Neoplasias de la Mama/complicaciones , Fatiga/etiología , Femenino , Sofocos/etiología , Humanos , Hipnosis/métodos , Menopausia/psicología , Persona de Mediana Edad , Proyectos Piloto , Índice de Severidad de la Enfermedad , Trastornos del Inicio y del Mantenimiento del Sueño/etiología , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA